drugset / Trial / NCT03993353
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.
Timeline
- Start
- 2020-04-07
- Primary completion
- 2022-04-16
- Completion
- 2024-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Tadalafil | Small molecule | 10 mg | Oral |